145 related articles for article (PubMed ID: 22580252)
21. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial.
Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Kim HS; Park SJ
JACC Cardiovasc Interv; 2011 Mar; 4(3):310-6. PubMed ID: 21435609
[TBL] [Abstract][Full Text] [Related]
22. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
[TBL] [Abstract][Full Text] [Related]
23. The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions.
Grube E; Chevalier B; Smits P; Džavík V; Patel TM; Mullasari AS; Wöhrle J; Stuteville M; Dorange C; Kaul U;
JACC Cardiovasc Interv; 2011 Feb; 4(2):168-75. PubMed ID: 21349455
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes after unrestricted implantation of everolimus-eluting stents.
Latib A; Ferri L; Ielasi A; Godino C; Chieffo A; Magni V; Bassanelli G; Sharp AS; Gerber R; Michev I; Carlino M; Airoldi F; Sangiorgi GM; Montorfano M; Colombo A
JACC Cardiovasc Interv; 2009 Dec; 2(12):1219-26. PubMed ID: 20129548
[TBL] [Abstract][Full Text] [Related]
25. Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial.
Onuma Y; Miquel-Hebert K; Serruys PW;
EuroIntervention; 2013 Jan; 8(9):1047-51. PubMed ID: 23339811
[TBL] [Abstract][Full Text] [Related]
26. Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials.
Cassese S; Piccolo R; Galasso G; De Rosa R; Piscione F
Int J Cardiol; 2011 Jul; 150(1):84-9. PubMed ID: 21315461
[TBL] [Abstract][Full Text] [Related]
27. Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials.
Kereiakes DJ; Smits PC; Kedhi E; Parise H; Fahy M; Serruys PW; Stone GW
EuroIntervention; 2011 May; 7(1):74-83. PubMed ID: 21550906
[TBL] [Abstract][Full Text] [Related]
28. Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials.
Kedhi E; Stone GW; Kereiakes DJ; Serruys PW; Parise H; Fahy M; Simonton CA; Sudhir K; Sood P; Smits PC
EuroIntervention; 2012 Sep; 8(5):599-606. PubMed ID: 22995087
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.
Simsek C; Räber L; Magro M; Boersma E; Onuma Y; Stefanini GG; Zanchin T; Kalesan B; Wenaweser P; Jüni P; van Geuns RJ; van Domburg RT; Windecker S; Serruys PW
Int J Cardiol; 2013 Dec; 170(1):36-42. PubMed ID: 24196314
[TBL] [Abstract][Full Text] [Related]
30. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial.
Lansky AJ; Ng VG; Mutlu H; Cristea E; Guiran JB; Midei M; Newman W; Sanz M; Sood P; Doostzadeh J; Su X; White R; Cao S; Sudhir K; Stone GW
Catheter Cardiovasc Interv; 2009 Nov; 74(5):719-27. PubMed ID: 19530147
[TBL] [Abstract][Full Text] [Related]
31. Sirolimus- versus paclitaxel-eluting stents for coronary bifurcations intervention: a meta-analysis of five clinical trials.
Qian J; Chen Z; Ma J; Ge J
Catheter Cardiovasc Interv; 2012 Oct; 80(4):507-13. PubMed ID: 22045690
[TBL] [Abstract][Full Text] [Related]
32. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials.
Palmerini T; Kirtane AJ; Serruys PW; Smits PC; Kedhi E; Kereiakes D; Sangiorgi D; Bacchi Reggiani L; Kaiser C; Kim HS; De Waha A; Ribichini F; Stone GW
Circ Cardiovasc Interv; 2012 Jun; 5(3):357-64. PubMed ID: 22668554
[TBL] [Abstract][Full Text] [Related]
33. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.
Räber L; Magro M; Stefanini GG; Kalesan B; van Domburg RT; Onuma Y; Wenaweser P; Daemen J; Meier B; Jüni P; Serruys PW; Windecker S
Circulation; 2012 Mar; 125(9):1110-21. PubMed ID: 22302840
[TBL] [Abstract][Full Text] [Related]
34. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
[TBL] [Abstract][Full Text] [Related]
35. Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents.
Mahmoudi M; Delhaye C; Wakabayashi K; Ben-Dor I; Gonzalez MA; Maluenda G; Gaglia MA; Torguson R; Xue Z; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R
Am J Cardiol; 2011 Jun; 107(12):1757-62. PubMed ID: 21497782
[TBL] [Abstract][Full Text] [Related]
36. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
Muramatsu T; Onuma Y; van Geuns RJ; Chevalier B; Patel TM; Seth A; Diletti R; García-García HM; Dorange CC; Veldhof S; Cheong WF; Ozaki Y; Whitbourn R; Bartorelli A; Stone GW; Abizaid A; Serruys PW; ; ; ; ; ;
JACC Cardiovasc Interv; 2014 May; 7(5):482-93. PubMed ID: 24746650
[TBL] [Abstract][Full Text] [Related]
37. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes after treating acute coronary syndrome patients with a drug-eluting stent: results from REWARDS-EMI (Endeavor for Myocardial Infarction Registry).
Dvir D; Barbash IM; Torguson R; Badr S; Sardi GL; Laynez-Carnicero A; Ben-Dor I; Satler LF; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2013; 14(3):128-33. PubMed ID: 23642502
[TBL] [Abstract][Full Text] [Related]
39. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
[TBL] [Abstract][Full Text] [Related]
40. Everolimus-eluting versus paclitaxel-eluting stents for treatment of bare metal stent restenosis.
Almalla M; Schröder JW; Pross V; Stegemann E; Marx N; Hoffmann R
Am J Cardiol; 2011 Aug; 108(4):518-22. PubMed ID: 21624553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
